Friday, November 20, 2026

Korea Pharmaceutical and Bio-Pharma Manufacturers Association Discusses Responses to CSO and AI Marketing Regulations, Holds Ethical Management Workshop

Input
2026-11-20 14:58:47
Updated
2026-11-20 14:58:47
Exterior of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association
[Financial News] The Korea Pharmaceutical and Bio-Pharma Manufacturers Association has created a forum for discussions on ethical management to address regulatory changes in the pharmaceutical and bio-pharmaceutical industry, including tighter oversight of pharmaceutical sales organizations (CSOs) and expanded use of artificial intelligence (AI) in marketing.
The association said on the 20th that it held the “2026 Second-Half KPBMA Ethical Management Workshop” on the 19th at its auditorium in Seocho District, Seoul. About 250 people responsible for fair trade compliance programs (CP) at pharmaceutical and bio-pharmaceutical companies attended the event, which was held both online and in person.
The workshop covered government policies on the proper distribution of pharmaceuticals and medical devices, CSO regulations, pharmaceutical advertising standards, corporate responses to the restructuring of the investigative system, whistleblower programs, and legal issues related to digital healthcare and AI marketing.
Jeong A-young, an official at the Ministry of Health and Welfare, outlined policy directions alongside the results of a survey on CSOs. These included tougher reporting and document-submission requirements to improve transparency in the outsourcing and subcontracting of promotional sales, as well as an overhaul of the management and oversight system. She also shared updates on institutional improvements related to medical device purchasing intermediaries.
Attorney Son Jeong-hyeon of Shin & Kim LLC explained legal risks related to CSOs, including multilevel subcontracting, high commission rates and illegal kickbacks, as well as issues pharmaceutical companies should consider in contracting and management. Attorney An Hyo-jun of Bae, Kim & Lee LLC (BKL) reviewed major violations related to pharmaceutical advertising, including advertising beyond approved indications, and the standards for compliance.
The workshop also discussed corporate responses at each stage of an investigation, including search and seizure under the restructured investigative system; legal liability for misconduct by executives and employees; and ways to operate whistleblower programs. Regulatory issues that may arise in marketing based on new technologies were also discussed, including digital medical devices, telemedicine, false or exaggerated claims in AI-generated advertisements, copyright and the handling of personal information.
Association Chairman Noh Yun-Hong said, “The industry environment is changing rapidly, with the CSO market expanding, oversight being strengthened, and digital healthcare and AI-powered marketing growing.” He added, “Ethical management is a key foundation supporting companies’ sustainability and trust across the industry.”
[email protected] Jung Sang-hee Reporter